Over the past two decades, the downregulation of TLR4 signaling has been shown to be potentially beneficial in the treatment of arthritis [10], viral infection-related pathology [6,11], and sepsis syndrome [12,13]. The gene discussed is TLR4; the disease is systemic inflammatory response syndrome.